OMER
Omeros Corp Health Care Pharmaceutical Preparations Russell 3000
$18.44Close
$1.3BMarket cap
$6.28 – $21.0552-week range
Nov 12, 2026Next report
Highlights
Strengths
- Leading the market RS 95 · stronger than 95% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 11.3%
price change
1mo
down 3.2%
price change
12-month return
up 145%
market up 11% ·
its own up 129%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 8.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
—
return on equity
Free cash margin
—
-$116.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 47% ($0.2B → $0.1B)
Trade setup
ATR%
4.9%
$0.91 a day · 2×ATR $16.62
RS
95 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.6×
vs 50-day average
Up/down volume
1.06
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$121.2M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Shareholders diluted The share count rose 23.5% over the year, from 58m to 72m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Last shock
Oct 16, 2026-14% in one session2.2× volumeno filing matched+14% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $73.8M | — | — | — | — | — |
| Gross margin | 99% | — | — | — | — | — |
| Operating income | -$156.9M | -$173.6M | -$163.4M | -$164.5M | -$167.0M | -$122.8M |
| Net income | -$138.1M | $194.2M | $47.4M | -$117.8M | -$156.8M | -$3.4M |
| Net margin | -187% | — | — | — | — | — |
| Earnings per share | -$2.41 | $3.12 | $0.76 | -$1.88 | -$2.70 | -$0.05 |
| Free cash flow | -$100.4M | -$110.0M | -$86.6M | $74.3M | -$149.0M | -$116.2M |
| Free cash margin | -136% | — | — | — | — | — |
| Cash | $10.5M | $100.8M | $11.0M | $7.1M | $3.4M | $9.7M |
| Long-term debt | $236.3M | $313.5M | $315.3M | $213.2M | $164.9M | $87.9M |
| Shareholders' equity | -$120.8M | $23.8M | $85.7M | -$25.0M | -$182.6M | -$121.2M |
| Shares outstanding | 61.67m | 62.63m | 62.83m | 61.13m | 58.04m | 71.67m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 31, 2026 | Annual ↗ | Dec 31, 2025 | 90d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 15, 2025 | Quarterly ↗ | Mar 31, 2025 | 45d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Apr 1, 2024 | Annual ↗ | Dec 31, 2023 | 92d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Director or officer change ↗ |
| Aug 13, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Results ↗ |
| Jul 20, 2026 | Other events ↗ |
| Jul 6, 2026 | Other events ↗ |
| Jun 25, 2026 | Shareholder vote ↗ |
| Jun 18, 2026 | Other events ↗ |
| May 13, 2026 | Results ↗ |
| Mar 31, 2026 | Results ↗ |
| Jan 7, 2026 | Results ↗ |
| Dec 29, 2025 | Other events ↗ |
| Dec 1, 2025 | Agreement ended · Acquisition or disposal · Other events ↗ |